As NZT points out, the Ph1 definitely DID meet its Primary...

As NZT points out, the Ph1 definitely DID meet its Primary Endpoint AND demonstrated promising biological effects on established scars.The 42 patients with mature scars (over one year old and at least 10 cm² in size) applied either SNT-6302 or a placebo cream three times a week for three months. The treatment was well tolerated, with no serious adverse events reported . Biochemical analyses revealed a 66% reduction in lysyl oxidase (LOX) activity and a 30% decrease in hydroxyproline levels, indicating significant remodeling of scar tissue . LOX enzymes are responsible for the cross-linking of collagen fibers, a key process in scar formation. By inhibiting these enzymes, SNT-6302 effectively reduced excess collagen in the scars. Advanced imaging techniques, such as Optical Coherence Tomography (OCT), showed that treated scars exhibited structural and biological characteristics closer to normal, uninjured skin compared to the placebo group .

To your point that it didn't change scar appearance (of scars over 1 year old), yes, while the three-month duration of the study was insufficient to observe visible changes in scar appearance, the significant biochemical and structural improvements suggest that longer treatment periods may lead to noticeable cosmetic benefits. These findings support further clinical development of SNT-6302 for both the treatment and prevention of skin scarring.

Not sure how you view that as a fail, nor Dr Fiona Woods comments after the trial - "“This exploratory clinical study has significantly enhanced our understanding of the role of LOX enzymes in scarring and the scar process itself. SNT‐6302 safely inhibits these key enzymes to a significant degree and leads directly to an unprecedented change to the scar composition that we have not seen with any other form of treatment. We estimate that up to 50% of the excess collagen in these patients’ scars has been removed, and while the length of this Phase 1c safety study was not sufficient to change the appearance of an established scar, the remodelling process will be ongoing. I’m confident we would see an improvement in scar appearance and physical characteristics if we observed them for longer.